Acne News

Healio has compiled June’s most-read news in dermatology.

The TheraClearX Acne device was efficacious in reducing mild to moderate acne in all skin types, according to a study.

Antihypertensive medications may lower patients’ risk for developing acne within 5 years of therapy initiation, according to a study.

Fixed-dose clindamycin phosphate 1.2%, adapalene 0.15% and benzoyl peroxide 3.1% gel demonstrated safety and efficacy across all age groups for the treatment of acne, according to a post hoc analysis.

Dapsone gel 7.5% demonstrated safety, tolerability and efficacy for the treatment of acne vulgaris in patients with skin of color, according to a study.

Atrophic acne scars are difficult to treat, but a new study found that combination therapy with microneedling and 60% phenol and 0.2% croton oil was an effective and safe treatment option.

Isotretinoin is generally effective and well tolerated for acne treatment in patients receiving masculinizing gender-affirming care, but barriers can impede treatment success, according to a study.

Rehmannia glutinosa leaf extract supplementation improved acne severity, skin hydration and the quality of life of women with acne vulgaris, according to a study.

Isotretinoin is associated with a clinically marginal increased risk for severe adverse events, leading researchers to advise routine blood testing commence shortly after initiation, according to a study.

Trifarotene cream 0.005%, in conjunction with a proper skincare regimen, reduced acne lesions and acne-induced hyperpigmentation within 24 weeks, according to study.